Todd Anderman, JD
Todd Anderman is Chief Legal Officer and Corporate Secretary of Ocular Therapeutix. Prior to joining the company, Mr. Anderman was Senior Vice President, Chief Legal Officer and Corporate Secretary of Iveric Bio, where he led the company’s legal, intellectual property and compliance functions. Prior to that, Mr. Anderman was a corporate attorney for several years […]
Steve Meyers
Steve Meyers has over 20 years of commercial experience that includes several buy and bill, specialty pharmacy and innovative technology product launches in highly competitive markets. Mr. Meyers has served in other commercial capacities at leading biotechnology organizations including Regeneron, AbbVie, and Procter & Gamble. Prior to joining Ocular, Mr. Meyers served as Vice President […]
Namrata Saroj, OD
Namrata Saroj, OD brings over 20 years of experience focusing on global development and commercialization of drugs and technologies advancing ophthalmic care. Her extensive understanding of the ophthalmology clinical and commercial landscapes is founded on her diverse experiences working across multiple programs. She has collaborated with multiple companies across various stages from early start-ups to late-stage […]
Sanjay Nayak, MBBS, PhD
Sanjay Nayak, MBBS, PhD, was the founder and fund manager of a biotech-focused private investment fund, Sentiv Capital. The fund invested in public and private biotechnology companies and has been a sought-after co-investor, based on the quality and depth of his due diligence and contributions to investment strategy. Dr. Nayak’s investment approach integrated more than […]
Peter Jarrett, PhD
Peter Jarrett, PhD, has more than 40 years of R&D experience, ranging from discovery to commercialization. Dr. Jarrett joined Ocular Therapeutix in 2007. Previously, he was Vice President of R&D at Focal, subsequently being named VP of Biomaterials R&D at Genzyme upon the latter company’s acquisition of Focal. Dr. Jarrett began his career in Corporate […]
Peter K. Kaiser, MD
Prior to joining the Ocular Therapeutix management team, Peter K. Kaiser, MD, had been the Chief Medical Advisor – Retina since 2022. Dr. Kaiser graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency […]
Nadia K. Waheed, MD, MPH
Dr. Waheed brings almost 20 years of experience in ophthalmology and leadership to Ocular through her work as a retinal surgeon, scientist, clinical researcher and Board Member in academic and research settings. She has a proven track record in clinical development and as a CMO, with experience in all phases of development including clinical trial design […]
Jeffrey S. Heier, MD
Jeffrey S. Heier, MD, is and will continue to serve as the Director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston (OCB), one of the largest multi-specialty ophthalmology practices in the United States. Dr. Heier served as Co-President & Medical Director of OCB from 2016-2020. Dr. Heier is the […]
Donald Notman
Mr. Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Mr. Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Mr. Notman […]
Pravin U. Dugel, MD
Pravin U. Dugel, MD has held previous leadership roles including President of IVERIC Bio, Inc., Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr. Dugel has authored more than […]